Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
AssigneeNovImmune S.A.
InventorsKrzysztof Masternak, Olivier Leger
Life of this patent
Estimating the term…
Abstract
This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
Claims25
An isolated antibody, or an antigen-binding fragment thereof, that (1) binds IL-17A homodimer, IL-17F homodimer and the IL-17A/IL-17F heterodimeric complex, wherein the antibody (2) exhibits (i) a binding affinity of at least 100 pM or less against the IL-17A homodimer, (ii) a binding affinity of at least 300 pM or less against the IL-17F homodimer, (iii) a binding affinity of at least 400 pM or less against the IL-17A/IL-17F heterodimeric complex, (iv) a neutralizing ability of at least 13 nM or less against the IL-17A homodimer, (v) a neutralizing ability of at least 120 nM or less against the IL-17F homodimer, and (vi) a neutralizing ability of at least 31 nM or less against the IL-17A/IL-17F heterodimeric complex, wherein the binding affinity is measured by surface plasmon resonance, and the neutralizing ability is determined by measuring IL-6 secretion by IL-17-stimulated mouse or human embryonic fibroblasts.
An isolated antibody, or an antigen-binding fragment thereof, which comprises:
- (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 57, 60, 66, 69, 76, 79, 82, or 85;
- (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 58, 61, 63, 65, 67, 70, 72, 74, 77, 80, 83, 86, 93 or 94;
- (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 59, 62, 64, 68, 71, 73, 75, 78, 81, 84, 87, or 95;
- (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO:
- 96, 101, 104, 107 or 110;
- (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO:
- 97, 102, 105 or 108;
- and
- (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO:
- 98, 99, 100, 103, 106, 109, or 111,
- wherein said antibody binds IL-17F and IL-17A.
An antibody comprising a VH sequence of SEQ ID NO:
- 2, 6, 8, 10, 14, 18, 20, 24, 28, 32, 38, 52, or 54, and a VL sequence SEQ ID NO:
- 4, 12, 16, 22, 26, 30, 36, 40 or 56, or an antigen-binding fragment thereof.
Dependencies are inferred from the claim text.